ARCHIVES

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

This article is from The Cancer Letter archive.

Vol. 02 No. 37 | September 10, 1976

Download PDF Visit The Full Archive

Related Articles

NCI Plans $175 Million In Program Cuts To Cover Deficit, Fund New Initiatives

November 17, 2006

Oxaliplatin Added To 5-FU/LV Improves Disease-Free Survival In Early Colon Cancer

June 24, 2005

Women’s Caucus Calls For Wide Mammogram Payment

March 18, 1994

100 NSABP Sites May Enroll Patients; Only One Trial Open

July 15, 1994

Women’s Health Initiative Trial Produced $37.1 Billion in Returns

May 9, 2014

As For-Profits Provide Phase I Studies, NCI Seeks to Look Deeper and Learn More

April 6, 2012